Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
2021 · Journal of Clinical Oncology · 625 citations
https://doi.org/10.1200/jco.20.01605
A
Ang Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
172
Papers
5.1K
Citations
26
h-index
45
i10-index
Ang Li is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Pancreatitis Pathology and Treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 26, co-authored 147 publications.
ORCID: 0000-0002-7403-2705Papers by this author
worksFour-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
2019 · The Lancet Oncology · 361 citations
https://doi.org/10.1016/s1470-2045(19)30407-3
Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis
2017 · BMC Surgery · 52 citations
https://doi.org/10.1186/s12893-017-0259-1
Impact of an AI-based laparoscopic cholecystectomy coaching program on the surgical performance: a randomized controlled trial
2024 · International Journal of Surgery · 29 citations
https://doi.org/10.1097/js9.0000000000001798
TNFSF15 promoter polymorphisms increase the susceptibility to small cell lung cancer: a case-control study
2019 · BMC Medical Genetics · 10 citations
https://doi.org/10.1186/s12881-019-0762-6
Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
2022 · Scientific Reports · 5 citations
https://doi.org/10.1038/s41598-022-25050-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat